Heparin Sodium
FDA Recall NDC 0409-7620

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.
The FDA has identified 3 recorded enforcement report(s) associated with Heparin Sodium (NDC 0409-7620). A significant event, classified as Class II, was initiated on Dec 29, 2022 by Hospira, Inc.. The reported reason for this action was: "Lack of assurance of sterility: Bags have the potential to leak."

This specific recall has a current status of COMPLETED, indicating that the FDA considers the recall process finished or the product successfully recovered.

Reported Recall Events

December 2022 Class II Recall: Lack of assurance of sterility

Recall Number
Class II Completed
Reason for Recall
Lack of assurance of sterility: Bags have the potential to leak.
Initiated
Dec 29, 2022
Reported
Jan 11, 2023
Quantity
62,088 bags

Recall Profile & Regulatory Data

Event ID
91379
Classification
Class II
Enforcement Status
Completed
Recalling Firm
Pfizer Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA.
Product Description
Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/mL) in 0.9% Sodium Chloride Injection, 1,000 mL bags, a) Case (NDC 0409-7620-59), b) Single Unit (NDC 0409-7620-49), Rx only, Distributed By Hospira, Inc., Lake Forest, IL 60045 USA,
Batch or Lot Expiration Information
Lot# Lot: 5935283, Exp. 12/01/2023
Affected Packages Involved in this Recall
0409-7620-13Product
0409-7620-03Product
0409-7620-49Product
0409-7620-59Product
0409-1005-01Product
0409-1005-20Product
0409-2222-01Product
0409-2222-12Product

September 2014 Class I Recall: Presence of Particulate Matter

Recall Number
Class I Terminated
Reason for Recall
Presence of Particulate Matter: A particulate, confirmed as human hair, was found sealed between the tube and film at the round seal of the unused administrative port of the container.
Initiated
Sep 11, 2014
Reported
Dec 31, 2014
Quantity
63,378 flexible container units

Recall Profile & Regulatory Data

Event ID
69214
Classification
Class I
Enforcement Status
Terminated
Recalling Firm
Hospira Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide
Termination Date
Jan 04, 2016
Product Description
HEPARIN SODIUM, 1000 USP Heparin Units/500 mL (2 USP Heparin Units/mL), in 0.9% Sodium Chloride Injection, 500 mL flexible container unit, Rx only, Hospira Inc., Lake Forest, IL 60045, NDC 0409-7620-03
Batch or Lot Expiration Information
Lot# : 41-046-JT, Exp 11/01/2015
Affected Packages Involved in this Recall
0409-7620-13Product
0409-7620-03Product
0409-7620-49Product
0409-7620-59Product
0409-1005-01Product
0409-1005-20Product
0409-2222-01Product
0409-2222-12Product

January 2014 Class II Recall: Lack of Assurance of Sterility; potential leakage from administrative port.

Recall Number
Class II Terminated
Reason for Recall
Lack of Assurance of Sterility; potential leakage from administrative port.
Initiated
Jan 09, 2014
Reported
Feb 05, 2014
Quantity
27780 bags

Recall Profile & Regulatory Data

Event ID
67317
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
Hospira Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide including Puerto Rico
Termination Date
May 19, 2015
Product Description
Heparin Sodium 2000 USP Heparin Units per 1000 mL (2 USP Heparin Units/mL) in 0.9% Sodium Chloride Injection, Rx only. Hospira, Lake Forest, IL 60045. NDC 0409-7620-59.
Batch or Lot Expiration Information
Lot# : 26-125-JT, Exp: 8/14
Affected Packages Involved in this Recall
0409-7620-13Product
0409-7620-03Product
0409-7620-49Product
0409-7620-59Product
0409-1005-01Product
0409-1005-20Product
0409-2222-01Product
0409-2222-12Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.